At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 48 enrolled
Drug / intervention
AZD4041 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I Randomized, Double-blind Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD4041 Following Single Ascending Dose Administration to Healthy Volunteers
In Brief
A Phase 1 clinical trial evaluating AZD4041 and Placebo for Smoking Cessation. Completed, enrolled 48 participants across 2 sites.
Detailed Summary
This is a Phase I, first-in-human (FIH), single-center, randomized, double-blind, placebo controlled, single ascending dose, sequential group study in healthy vasectomized male and female subjects of non-childbearing potential, aged 18 to 65 years.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmoking Cessation
CountriesUnited States
CollaboratorsNational Institutes of Health (NIH), Eolas Therapeutics INC.
Timeline
Phase 1CompletedFinished
2020202120222023202420252026
First PostedSep 2019
Enrollment StartOct 2019
Primary CompletionJan 2022
TodayJul 2026
First PostedSep 3, 2019
Enrollment StartOct 3, 2019
Primary CompletionJan 2, 2022
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 6.8 years ago
Interventions
AZD4041drug
Administration by Oral syringe
Placebodrug
Administration by Oral syringe